Seaport Therapeutics, Inc. Common Stock

The mean of analysts' price targets for Seaport Therapeutics, Inc (SPTX) points to a 77.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

BOSTON--(BUSINESS WIRE)--Seaport Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress.

Seaport Therapeutics leverages proprietary Glyph technology to enhance bioavailability and safety for CNS drugs, targeting MDD and GAD markets. SPTX maintains a cash runway into 2029, with $427.3 million at June 30, trading at a forward book value discount versus sector peers. Recent clean driving data for GlyphAllo and strong PK data for GlyphAgo de-risk regulatory and commercial pathways ahead of the pivotal BUOY-1 readout.

[url="]PureTech Health plc[/url] (LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and tran

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Presents Data from Phase 1 Trial of GlyphAgo at European College of Neuropsychopharmacology Congress.

[url="]Seaport Therapeutics, Inc.[/url] (Nasdaq: SPTX) (“Seaport” or the “Company”), a clinical-stage therapeutics company developing novel neuropsychia

BOSTON--(BUSINESS WIRE)--Seaport Therapeutics, Inc. (Nasdaq: SPTX) (“Seaport” or the “Company”), a clinical-stage therapeutics company developing novel neuropsychiatric medicines, today announced the presentation of Phase 1 clinical data for GlyphAgo™ (SPT-320 or Glyph Agomelatine) at the 39th European College of Neuropsychopharmacology (ECNP) Congress, taking place October 10-13, 2026, in Munich, Germany. The poster represents the first scientific presentation of data from the GlyphAgo Phase 1.

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Doses First Patient in GlyphAgo Phase 2a Trial in Generalized Anxiety Disorder & Sleep Disturbance.

BOSTON--(BUSINESS WIRE)--Seaport Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgo in Patients with Generalized Anxiety Disorder & Sleep Disturbance.

Seaport Therapeutics, Inc. (NASDAQ: SPTX - Get Free Report) gapped up before the market opened on Thursday. The stock had previously closed at $18.69, but opened at $20.12. Seaport Therapeutics shares last traded at $19.91, with a volume of 5,471 shares trading hands. Analyst Upgrades and Downgrades Several equities analysts recently issued reports on the stock.

Seaport Therapeutics, Inc. (NASDAQ: SPTX - Get Free Report) shares gapped down before the market opened on Wednesday. The stock had previously closed at $19.64, but opened at $18.85. Seaport Therapeutics shares last traded at $18.49, with a volume of 10,399 shares. Wall Street Analyst Weigh In Several research firms recently issued reports on SPTX. Weiss

Seaport Therapeutics, Inc. (NASDAQ: SPTX - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the twelve brokerages that are presently covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating, six have assigned a buy rating and one

BOSTON--(BUSINESS WIRE)--Seaport Therapeutics, Inc. (Nasdaq: SPTX) (“Seaport” or the “Company”), a clinical-stage therapeutics company that is inventing and developing novel neuropsychiatric medicines, today announced that members of its management team will participate in a series of additional upcoming investor conferences in September, including a company presentation and panel discussion featuring Co-Founder and Chief Executive Officer, Daphne Zohar, at the Goldman Sachs Life Sciences Sympo.

Seaport Therapeutics, Inc. (SPTX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

[url="]PureTech Health plc[/url] (LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and tran

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo in Healthy Volunteers.

BOSTON--(BUSINESS WIRE)--Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers.

Seaport Therapeutics just went public with a prodrug platform that has attracted board members from two of the biggest neuroscience acquisitions in recent history. The question is whether the same giants who funded those deals are already circling for a third.

Seaport Therapeutics, Inc. (NASDAQ: SPTX - Get Free Report)'s stock price hit a new 52-week high during trading on Tuesday. The company traded as high as $25.07 and last traded at $24.40, with a volume of 98612 shares. The stock had previously closed at $24.22. Analyst Ratings Changes Several equities research analysts recently commented on

Seaport Therapeutics leverages its Glyph platform to transform clinically validated molecules with poor delivery into proprietary, patent-protected prodrugs, reducing biological risk. GlyphAllo's Phase 2b BUOY-1 trial in MDD targets a differentiated profile, with top-line data expected in H1 2027 and a focus on anxious distress subpopulations. GlyphAgo's strong Phase 1 PK data and platform repeatability support SPTX's strategy, with Phase 2a in GAD set for H2 2026 and registration-enabling studi…